Christopher M OConnor
Overview
Explore the profile of Christopher M OConnor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
735
Citations
24024
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Minciunescu A, Rosner C, Kepplinger D, Del Castillo T, Overbeck D, Levy W, et al.
JACC Heart Fail
. 2024 Jun;
12(8):1487-1493.
PMID: 38934962
Guideline-directed medical therapy utilization in patients with heart failure with reduced ejection fraction (HFrEF) remains low despite benefits in morbidity and mortality. The authors describe a unique quality improvement initiative...
12.
Shah P, Looby M, Dimond M, Bagchi P, Shah B, Isseh I, et al.
JACC Heart Fail
. 2024 May;
12(9):1540-1549.
PMID: 38795110
Background: Patients receiving left ventricular assist device (LVAD) support require long-term anticoagulation to reduce the risk of thromboembolic complications. Apixaban is a direct oral anticoagulant that has become first-line therapy;...
13.
14.
Gouda P, Rathwell S, Colin-Ramirez E, Felker G, Ross H, Escobedo J, et al.
Circ Cardiovasc Qual Outcomes
. 2024 Apr;
17(5):e010560.
PMID: 38567506
Background: In heart failure (HF) trials, there has been an emphasis on utilizing more patient-centered outcomes, including quality of life (QoL) and days alive and out of hospital. We aimed...
15.
Adamson P, Echols M, Defilippis E, Morris A, Bennett M, Abraham W, et al.
JACC Heart Fail
. 2024 Mar;
12(7):1212-1222.
PMID: 38530702
Background: Inadequate inclusion in clinical trial enrollment may contribute to health inequities by evaluating interventions in cohorts that do not fully represent target populations. Objectives: The aim of this study...
16.
Ezekowitz J, Alemayehu W, Edelmann F, Ponikowski P, Lam C, OConnor C, et al.
Eur J Heart Fail
. 2024 Mar;
26(3):628-637.
PMID: 38450878
Aims: In VICTORIA, vericiguat compared with placebo reduced the risk of cardiovascular death (CVD) and heart failure hospitalization (HFH) in patients enrolled after a worsening heart failure (WHF) event. We...
17.
Troendle J, Leifer E, Yang S, Jeffries N, Kim D, Joo J, et al.
Stat Med
. 2024 Feb;
43(10):1920-1932.
PMID: 38417455
Consider the choice of outcome for overall treatment benefit in a clinical trial which measures the first time to each of several clinical events. We describe several new variants of...
18.
Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction
Mentz R, Stebbins A, Butler J, Chiang C, Ezekowitz J, Hernandez A, et al.
JACC Heart Fail
. 2024 Feb;
12(5):839-846.
PMID: 38363272
Background: In VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction), vericiguat compared with placebo reduced cardiovascular death or heart failure (HF) hospitalization in patients with...
19.
Fuery M, Leifer E, Samsky M, Sen S, OConnor C, Fiuzat M, et al.
JACC Heart Fail
. 2023 Dec;
12(3):479-487.
PMID: 38127049
Background: Although clinical studies have demonstrated the association between a single N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurement and clinical outcomes in chronic heart failure, the biomarker is frequently measured serially...
20.
Dimond M, Ibrahim N, Fiuzat M, McMurray J, Lindenfeld J, Ahmad T, et al.
JACC Heart Fail
. 2023 Dec;
12(3):451-460.
PMID: 38099892
Heart failure (HF) is a complex syndrome traditionally classified by left ventricular ejection fraction (LVEF) cutpoints. Although LVEF is prognostic for risk of events and predictive of response to some...